Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

MyStart Health vs Vytora Health

MyStart Health
Graded #168

Lower grade

vs+5.200000000000003
Vytora Health
Graded #79

Higher grade

The verdict

Vytora Health takes it — 72.3/100 to 67.1/100.

Vytora Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Vytora Health is a 50-state-plus-DC telehealth platform offering compounded semaglutide and tirzepatide alongside brand-name Mounjaro and Zepbound, plus NAD+ and sermorelin peptides.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueVytora Health +11
48
59
Dose & formulationVytora Health +2
83
85
Clinical oversightVytora Health +12
84
96
Labs & monitoringMyStart Health +11
66
55
FulfillmentVytora Health +18
78
96
Contract termsMyStart Health +11
31
20
MyStart Health · left barVytora Health · right bar

The numbers

MetricMyStart HealthVytora Health
WeighScore67.1/10072.3/100
GradeCC
Scorecard rank#168#79
Semaglutide$299/mo (all doses, compounded)$180/mo (all doses, compounded)
Tirzepatide$299/mo (all doses, compounded)$249/mo (all doses, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
MyStart Health

Graded #168 · C

Strengths

  • Price Lock Guarantee — your $299 base rate doesn't rise as your dose escalates
  • Fast onboarding: roughly 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
  • 24/7 care team access with unlimited clinician messaging included
  • LegitScript certified
  • Clear Section 503A compounding disclosure on every landing page

Where it loses points

  • Not BBB accredited — C+ rating with 10 complaints, mostly shipping delays and support access
  • Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
  • Markets oral tirzepatide, but no FDA-approved oral tirzepatide exists
  • Very new company (incorporated May 2024) with a limited track record
  • Pharmacy partners not named, so 503A compliance can't be independently verified
Vytora Health

Graded #79 · C

Strengths

  • All 50 states plus DC, with per-state video-vs-audio compliance disclosed
  • Both compounded and brand-name options on one platform — uncommon
  • LegitScript Approved and HIPAA compliant
  • Pharmacy partners named publicly: Vials Pharmacy (TX) and Greenwich Biosciences
  • Operating entity disclosed: Wasef Health, PC (Pinellas Park, FL)

Where it loses points

  • Brand-name Mounjaro/Zepbound at $1,399/mo is near retail — insured patients may do better via LillyDirect Self Pay ($449-$699/mo)
  • Compounded tirzepatide at $249/mo is mid-market, above the $149-199 floor
  • Dose tiers aren't broken out — 'all doses included' means low-dose patients pay the same as high-dose
  • Initial consultation cost not shown on the public pricing page
  • Limited per-prescriber state licensure detail

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard